Vinorelbine—gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC phase II trial

摘要: Summary Purpose: The purpose of the present phase II trial was to determine efficacy and toxicity vinorelbine-gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC). Patients methods: From December 1997 February 1999, 78 chemotherapy-naive (median age 60 years, Karnofsky performance status 100, 90, 80 70 5%, 41%, 36% 18% patients, respectively) stage IIIB (17%) or IV (83%) NSCLC (65% adenocarcinomas, 22% squamous-cell carcinomas, 10% large-cell 3% mixed-cell carcinomas) received 25 mg/m 2 vinorelbine 1200 gemcitabine on days 1, 8 15 a four-week cycle. Results: In an intent-to-treat analysis, partial responses were seen 19% patients. median duration response 4.4 months. survival time seven months one-year rate 32%. Myelosuppression main side effect WHO grade 3/4 neutropenia thrombocytopenia 35% 11% respectively. Other effects usually mild moderate. Conclusions: Vinorelbine-gemcitabine is active, well tolerated easy administer outpatient basis NSCLC. Thus randomized comparison this combination platinum-based protocols warranted